Tom Sherman has the experience to be a state senator
Oct. 24 — To the Editor:
In attending the Rye candidates’ forum last week, the difference between Dr. Tom Sherman and Mr. Dan Innis was very apparent.
Both are professionals in their field and their demeanor portrays them as confident and caring men.
But the devil is in the details.
There is a difference between running a business and running a senatorial district. As a business director, you have the authority and position to guide your organization in a certain direction. As a state senator, you are a servant for your constituents. Tom Sherman proved that last night and has the track record, as well.
Tom Sherman has represented the Rye – New Castle district for the past four years and he is a popular and respected as our state representative. He is well known for his open minded stance and being available for our opinions and positions.
Both as a private citizen, and a legislator, he has been intimately involved with the Seacoast cancer cluster. For our community, this is a serious and important concern and he is there with us.
Very important in the small state Senate population, Tom is a proven consensus builder who has a track record of working with Republicans to tackle some of our community's most important issues
Health care is an issue on everyone’s mind, whether you are a business owner, an employee, a parent, a family, a retiree – it affects all of us. During last night’s event, I specifically asked both candidates their position on Medicare expansion and its financial impact on New Hampshire. Mr. Innis did not answer the question and was very ambiguous about is position. He chose a diatribe on Obamacare. Dr. Sherman knew the facts, presented them to us and put his name on the line when it came to his position.
This campaign is not about Tom, it's not about Republicans versus Democrats and it's not about special interests. Tom's campaign is about our community.
I hope you will join me in doing what is best for our community by voting for Dr. Tom Sherman on Nov. 8.